cpg 1018

mAbexperimental

Clinical trial activity

6 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Dec 18, 2019 (NCT04177355)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06334393Phase 1Mar 25, 2024Valneva
NCT05606341Phase 1Nov 30, 2022Alzheimer's Association, New York University
NCT05506969Phase 2Aug 9, 2022Department of Defense, Dynavax Technologies Corporation
NCT05012787Phase 3Sep 13, 2021Clover Biopharmaceuticals
NCT04405908Phase 1Jun 20, 2020Clover Biopharmaceuticals
NCT04177355Phase 1Dec 18, 2019Dynavax Technologies Corporation, Emory University, HIV Vaccine Trials Network, Infectious Disease Research Institute, International AIDS Vaccine Initiative, National Institute of Allergy and Infectious Diseases (NIAID), University of Washington
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Clover BiopharmaceuticalsFor profit2222020
Dynavax Technologies CorporationFor profit2122019
Alzheimer's AssociationAcademic/Hospital1012022
Department of DefenseGovernment1012022
Emory UniversityAcademic/Hospital1012019
HIV Vaccine Trials NetworkAcademic/Hospital1012019
Infectious Disease Research InstituteAcademic/Hospital1012019
International AIDS Vaccine InitiativeAcademic/Hospital1012019
National Institute of Allergy and Infectious Diseases (NIAID)Government1112019
New York UniversityAcademic/Hospital1112022
University of WashingtonAcademic/Hospital1012019
ValnevaFor profit1112024
12 organizations
Page 1 / 1